BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:30 PM
 | 
Jul 28, 2010
 |  BC Extra  |  Top Story

FDA panel backs Brilinta

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 7-1 on Wednesday to recommend approval of Brilinta ticagrelor from AstraZeneca plc (LSE:AZN; NYSE:AZN) to reduce thrombotic events in patients with acute coronary syndrome (ACS). The panelists largely agreed that if approved, a U.S. postmarketing...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >